First subject dosed in phase I clinical study with eye-drop formulation of laquinimod  

NASDAQ Market News

NEXT STORY
New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq
PREV STORY
102,428 Orion Corporation A shares converted into B shares
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy

WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage ...

author_avatar
NASDAQ Market News

ELSALYS BIOTECH concludes with THEA a license option agreement on its ELB011 program in ophthalmology

    ELSALYS BIOTECH concludes with THEA a license option agreement on its ELB011 ...

author_avatar
NASDAQ Market News

Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A

Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to ...

author_avatar
NASDAQ Market News